Biogen (NASDAQ:BIIB) will be issuing its quarterly earnings data before the market opens on Thursday, January 25th. Analysts expect the company to announce earnings of $5.54 per share for the quarter.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Tuesday, October 24th. The biotechnology company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.70 by $0.61. Biogen had a return on equity of 38.51% and a net margin of 29.44%. The firm had revenue of $3.08 billion for the quarter, compared to analysts’ expectations of $3.05 billion. During the same quarter last year, the firm posted $5.19 EPS. The company’s revenue was up 4.1% compared to the same quarter last year. On average, analysts expect Biogen to post $22 EPS for the current fiscal year and $24 EPS for the next fiscal year.

Shares of Biogen (NASDAQ:BIIB) opened at $344.87 on Thursday. Biogen has a 1-year low of $244.28 and a 1-year high of $348.84. The firm has a market capitalization of $72,930.00, a PE ratio of 21.14, a price-to-earnings-growth ratio of 1.91 and a beta of 0.73. The company has a quick ratio of 1.90, a current ratio of 2.19 and a debt-to-equity ratio of 0.46.

In related news, CEO Michel Vounatsos purchased 780 shares of Biogen stock in a transaction that occurred on Saturday, December 29th. The shares were acquired at an average cost of $320.55 per share, for a total transaction of $250,029.00. Following the transaction, the chief executive officer now directly owns 4,879 shares in the company, valued at $1,563,963.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Alexander J. Denner purchased 30,000 shares of Biogen stock in a transaction that occurred on Wednesday, November 29th. The shares were bought at an average price of $317.36 per share, for a total transaction of $9,520,800.00. Following the completion of the transaction, the director now owns 10,029 shares in the company, valued at $3,182,803.44. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 31,560 shares of company stock worth $10,020,858. 0.25% of the stock is owned by corporate insiders.

BIIB has been the topic of several recent analyst reports. Citigroup cut Biogen from a “buy” rating to a “neutral” rating in a report on Monday, October 23rd. Mizuho set a $400.00 price target on Biogen and gave the company a “buy” rating in a report on Monday, November 13th. Credit Suisse Group raised Biogen from a “neutral” rating to an “outperform” rating and raised their price target for the company from $321.00 to $385.00 in a report on Wednesday, December 20th. Stifel Nicolaus reaffirmed a “hold” rating and issued a $300.00 price target on shares of Biogen in a report on Thursday, October 12th. Finally, Oppenheimer set a $350.00 price target on Biogen and gave the company a “buy” rating in a report on Monday, December 4th. Nine research analysts have rated the stock with a hold rating, twenty-two have given a buy rating and one has assigned a strong buy rating to the company’s stock. Biogen currently has a consensus rating of “Buy” and an average target price of $353.75.

COPYRIGHT VIOLATION NOTICE: This article was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2018/01/18/biogen-biib-scheduled-to-post-earnings-on-thursday.html.

About Biogen

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Earnings History for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.